← Eichor
Study identifier: NCT06838611 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgitation

Condition: Tricuspid Regurgitation · Heart Failure · Valve Heart Disease  ·  Sponsor: Medical University of Warsaw

PhaseN/A
Planned participants300
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this observational study is to characterize the population of patients qualified for transcatheter tricuspid valve interventions (TTVI). It is expected to: * Describe the profile of patients qualified for TTVI * Establish the most common causes for disqualification from TTVI * Evaluate the immediate and long-term efficacy of TTVI * Evaluate TTVI safety Participants will undergo a standard qualification procedure for TTVI and then will be subject to a follow-up consisting of clinical examination, echocardiography and laboratory testing.

This description comes directly from the study's public registry record.

Talk to the study team

Adam Rdzanek, MD PhD  ·  4822 599 19 51  ·  adam.rdzanek@wum.edu.pl

Mariusz Tomaniak, MD PhD Assoc. Prof.  ·  4822 599 19 51  ·  mariusz.tomaniak@wum.edu.pl

Always discuss trial participation with your own doctor first.

Locations (1)

First Department of Cardiology, Medical University of WarsawWarsaw, Masovian Voivodeship, PolandRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06838611